Stay updated on Benralizumab in Chronic Urticaria Clinical Trial
Sign up to get notified when there's something new on the Benralizumab in Chronic Urticaria Clinical Trial page.

Latest updates to the Benralizumab in Chronic Urticaria Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe page now includes a Locations section with state-level entries (Arizona, California, Florida, Georgia, Michigan, Ohio, Oklahoma, Texas) and the revision tag updated to v3.3.3, while the HHS Vulnerability Disclosure link is removed.SummaryDifference0.7%

- Check17 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check38 days agoChange DetectedRevision: v3.3.2 is now shown on the page, replacing Revision: v3.2.0. There are no changes to the study content or layout.SummaryDifference0.0%

- Check45 days agoChange DetectedThe government funding/operating status notice has been removed from the page. The study details and requirements remain unchanged.SummaryDifference0.3%

- Check59 days agoChange DetectedNo significant content changes detected; any differences appear to be minor formatting or layout adjustments that do not affect the study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check88 days agoChange DetectedAdded a government operating status notice and a v3.2.0 revision; removed the previous v3.1.0 revision.SummaryDifference2%

- Check95 days agoChange DetectedApparent page reversion to a new version (v3.1.0) while removing several drug-related topics (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs) and the prior version reference (v3.0.2).SummaryDifference0.2%

Stay in the know with updates to Benralizumab in Chronic Urticaria Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Benralizumab in Chronic Urticaria Clinical Trial page.